Work

P4 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis

Year: 2025

Type: conference-paper

DOI: 10.1136/gutjnl-2025-basl.21

Authors: Phil Newsome, Naim Alkhouri, Rebecca Taub, Dominic Labriola, Xiaomin Lu, Sam Moussa, Mazen Noureddin

Institutions: King's College London, Foundation for Liver Research, King's College Hospital, University of Birmingham, Arizona Liver Health, Madrigal Pharmaceuticals (United States), University of Arizona, Houston Institute for Clinical Research

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414963829

FWCI: 12.78

Cites:

Cited by: 1

Related to: